Big ideas often sprout from unexpected places like garages and dorm rooms, but three remarkable teenage brothers, Aviraj, Dhilen, and Brijen Soin, are proving that groundbreaking science and entrepreneurship don’t need a college degree. The siblings, still in high school, are the inspiration behind Soin Pharmaceuticals and the collaborators of several medical innovations, and their journey from a home lab to the forefront of pharmaceutical development is a one-of-a-kind story.
Childhood curiosity to invention
The Soin brothers’ passion for innovation began early, driven by a curiosity that went beyond typical childhood interests. Their first ventures included patents for a bioluminescent tornado maker toy and a GPS tracking system, and this inventive spirit, combined with a surprising knack for business, led them to cryptocurrency mining during the COVID-19 Pandemic.
They reinvested some of their earnings, not in traditional assets, but in Pokémon cards and an on demand 3D printing business. This collection and revenue later provided the initial funding for their startup, Soin Pharmaceuticals.
Innovations in pharmaceuticals…and beyond
Their most significant work to date focuses on developing revolutionary pharmaceutical solutions. Inspired by Aviraj’s amateur botany skills, they began creating topical pain relief creams made with botanical ingredients in a bid to use natural compounds for effective medicinal applications. They found success early when their topical creams they coinvented were acquired by a company on NASDAQ. (Pictured)
Beyond topical solutions, the Soin brothers have worked with contract manufacturers to engineer an innovative oral thin filament (OTF) drug delivery platform with similar botanicals. This innovative system aims to improve how drugs and nutrients can be administered, especially for people who have trouble swallowing pills. The OTF is an existing platform, offering a user-friendly and more efficient way to take medication.
Innovation in and out of the classroom
Their academic foundation at their school, Stanford Online High School, known for its challenging academic and entrepreneurial environment, has certainly helped them hone their various talents. It’s been a sandbox for the brothers’ “out-of-the-box” thinking and their many projects. But their interests reach beyond the lab and classroom in the form of their active participation in science fairs, international academic competitions, and medical conferences, where their peer-reviewed research has been accepted and published.
Aviraj Soin is the only rising junior in Ohio who qualified for the State Science Fair seven years in a row; all three brothers have won multiple state awards, including first at state and a global qualifier in Destination Imagination; and, additionally, they have participated in the Global Finals of the First Lego Robotics Competition. For the past two summers, Aviraj and Dhilen have been deeply involved in medical research, resulting in the acceptance and publication of six peer-reviewed abstracts each, with both older brothers acting as the first authors on several of the works.
Pioneering the future from a home lab
Soin Pharmaceuticals, a company they cofounded, represents their vision for more effective and accessible pharmaceutical solutions. The company’s unique selling point is its novel drug delivery systems, the OTF. The brothers’ ambition for the future is to guide the OTF platform through development, secure FDA approval, and ultimately, to launch it, making a huge difference in how medications and botanicals are taken.
The story of the Soin brothers is one of youthful ambition, scientific talent, and entrepreneurial drive. From a home lab to the very cutting edge of biotech, these teenage brothers aren’t just innovating concepts; they are transforming medicine, driven by a desire to make the world a better place through more accessible pharmaceutical solutions.
This article is for informational purposes only and does not substitute for professional medical advice. If you are seeking medical advice, diagnosis or treatment, please consult a medical professional or healthcare provider.
VentureBeat newsroom and editorial staff were not involved in the creation of this content.
